Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fludarabine + Melphalan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fludarabine | Fludara | FAMP|Fludarabine phosphate | Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) | |
Melphalan | Alkeran | Chemotherapy - Alkylating 18 | Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04205240 | Phase II | Cyclophosphamide + Daratumumab + Mycophenolate mofetil + Tacrolimus Fludarabine + Melphalan | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | Terminated | USA | 0 |
NCT02440464 | Phase II | Methotrexate + Tacrolimus Ixazomib Fludarabine + Melphalan Bortezomib | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | Completed | USA | 0 |
NCT02771197 | Phase II | Fludarabine + Melphalan Pembrolizumab | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | Completed | USA | 0 |
NCT02653196 | Phase II | Thiotepa Etoposide Alemtuzumab Palifermin Fludarabine + Melphalan Cyclosporine + Mycophenolate mofetil + Tacrolimus | A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | Terminated | USA | 0 |
NCT02333162 | Phase I | Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT02508038 | Phase I | Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa | Recruiting | USA | 0 |
NCT02528877 | Phase I | Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | Withdrawn | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT00577278 | Phase II | Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | Completed | USA | 0 |
NCT01453101 | Phase II | Fludarabine + Melphalan Bortezomib | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma | Completed | USA | 0 |